Neuroinflammation keynote · Pillar 3
Brain Flamed — Neuroinflammation and the Oral–Brain Axis
For medical congresses, longevity events and audiences over fifty · 40–60 minutes plus Q&A
In 2026, Lancet eBioMedicine published new research on the oral–brain axis and cognitive ageing. Research on P. gingivalis, gingipains and beta-amyloid has been building for years.
There are two ways to put that on a stage. One sells headlines but risks overstating the science.
This is the other one. The evidence-based version turns out to be the more interesting talk, and the one a medical programme committee can book with confidence.
DisclosureAssociations are documented. Causality is not proven. This keynote deliberately frames the topic as risk and correlation, never as prevention or cure.
The talk in one paragraph
Chronic oral inflammation and markers associated with neuroinflammation show consistent associations in the current literature, and plausible mechanistic pathways have been described. Causality, however, has not been established.
This keynote presents the evidence precisely as it stands: associations documented, causality still open. It then addresses the question that matters to the audience: how do you act sensibly on modifiable risk factors while the science is still evolving? Dr. Robert Bauder brings 30 years of clinical practice to a topic that is often handled either sensationally or not at all.
What the research shows — and what it does not
Associations between chronic oral inflammation and markers related to brain health and cognitive ageing have been documented across multiple study designs. Plausible mechanistic pathways have also been described.
Causality has not been established. Dr. Bauder says this clearly on stage before going any further. He then asks the more useful question: what do you do with a risk factor you can influence when the evidence shows an association but the causal relationship remains open? That is not a rhetorical question. It is a real decision many people over 50 face when thinking about long-term health.
Why this discipline is the selling point
Editors and programme committees have learned to be cautious with this topic because sensational claims are easy to make and difficult to defend. A speaker who clearly marks the boundaries of the evidence is credible where overstatement is not.
That makes this keynote particularly suitable for medical congresses, science-literate audiences and media formats where the distinction between what is known, what is strongly suggested and what remains open matters.
For your programme
Audiences: medical and longevity congresses, patient audiences over 50, health policy and prevention panels, science-literate media formats and family-facing events where cognitive ageing is a concern. Duration: 40–60 minutes plus Q&A. Scientific material: fully sourced slide deck. The reference list can be provided to organisers in advance, making review by programme or medical committees straightforward.
What happens on stage
Five acts. One mechanism.
The structure is planned; the delivery is not scripted.
01
The headline and the study behind it
What was actually measured, in which population and with which limitations.
02
The mechanism as currently described
Pathways, biological plausibility and the remaining gaps in the evidence.
03
Where the evidence stands, graded
Three levels: established, strongly suggested and open. Nothing moves up a level simply for dramatic effect.
04
Acting under uncertainty
Which risk factors in this area are modifiable today, and the reasoning behind addressing them while the science continues to evolve.
05
How to talk about it
A short section on communicating emerging science accurately without overclaiming, particularly relevant for medical and scientific audiences.
Take-aways
What your audience leaves with.
The current state of evidence on the oral–brain axis, stated in three sentences the audience can repeat accurately.
Which risk factors in this chain are modifiable today, and which are not.
A defensible way to act on emerging science without waiting for certainty or pretending it exists.
How to recognise overclaiming in this field — including in material the audience has already read.
Who books this talk
Medical and longevity congressesPatient audiences over 50Health policy and prevention panelsScience-literate media formatsFamily-facing events on cognitive ageing
Why Dr. Robert Bauder
A practising clinician, not only a science communicator.
He approaches the topic from the perspective of a practising clinician, while clearly distinguishing clinical observation from what the current research can actually establish.
30 years of clinical practice and more than 11,000 patients.
Founder of the Silent Root Cause® method and Bio-Longevity Dentistry®.
Peer-reviewed, PubMed-indexed multicentre study.
Clinical experience with the mechanisms and risk factors discussed in the keynote.
Frequently asked questions
Does the talk claim that oral health causes dementia?
No. It explicitly states that causality has not been established and makes that distinction clear from the beginning.
Is it suitable for a patient audience?
Yes. It is particularly useful for audiences who have encountered alarming headlines and want a clearer picture of what the current evidence does and does not show.
Can our medical board review the material in advance?
Yes. The slide deck and reference list can be made available before the event.
Does it work in a media interview format?
Yes. The graded-evidence structure works particularly well in interviews because it clearly separates established findings, emerging evidence and open questions.
DisclosureAssociations are documented. Causality is not proven. This keynote deliberately frames the topic as risk and correlation, never as prevention or cure.
Booking
Request this keynote — reply within 24 hours.
You receive availability and a topic recommendation within 24 hours. English or German. In person across Europe, virtual worldwide.